IL-17, IL-22, and IL-23, produced by Th17 cells, have been shown to play a major role in maintaining chronic inflammation in both psoriasis and SLE, and an upregulated Th17 immunologic response may explain the association between both conditions, as well as provide a therapeutic target for management of concomitant Ps and SLE [8,12,20-22]. This evidence concerns the gene IL22 and psoriasis.